Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer

被引：0
|
作者：
Rosen, Ezra Y. [1 ]
Italiano, Antoine [2 ]
Juric, Dejan [3 ]
Reeves, John A. [4 ]
Dima, Laura [5 ]
Brega, Nicoletta [4 ]
Drilon, Alexander [1 ,6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[5] Bayer Consumer Care AG, Basel, Switzerland
[6] Weill Cornell Med Coll, New York, NY USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS11-06
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Hong, D. S.
    Xu, R-H.
    McDermott, R. S.
    Shen, L.
    Dierselhuis, M. P.
    Doz, F.
    Tahara, M.
    Bernard-Gauthier, V.
    Norenberg, R.
    Brega, N.
    Laetsch, T. W.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S469 - S469
  • [42] Activity of Larotrectinib in TRK Fusion Lung Cancer
    Farago, A.
    Kummar, S.
    Moreno, V.
    Patel, J.
    Lassen, U.
    Rosen, L.
    Ku, N.
    Cox, M.
    Nanda, S.
    Childs, B.
    Hyman, D.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S283 - S284
  • [43] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
    Hong, David S.
    Drilon, Alexander E.
    Tan, Daniel Shao-Weng
    Lin, Jessica Jiyeong
    Kummar, Shivaani
    McDermott, Raymond S.
    Berlin, Jordan
    Italiano, Antoine
    Lassen, Ulrik Niels
    Leyvraz, Serge
    Tahara, Makoto
    Norenberg, Ricarda
    Burcoveanu, Domnita-Ileana
    Brega, Nicoletta
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
    Drilon, Alexander E.
    Hong, David S.
    Van Tilburg, Cornelis Martinus
    Doz, Francois
    Tan, Daniel S. W.
    Kummar, Shivaani
    Lin, Jessica Jiyeong
    McDermott, Raymond S.
    Zwaan, C. Michel
    Norenberg, Ricarda
    Fellous, Marc Mardoche
    Brega, Nicoletta
    Xu, Rui-Hua
    Laetsch, Theodore Willis
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
    Mascarenhas, Leo
    van Tilburg, Cornelis Martinus
    Zwaan, Francois Doz C. Michel
    Albert, Catherine M.
    Blattman, Claudia
    Geoerger, Birgit
    DuBois, Steven G.
    Federman, Noah
    Nagasubramanian, Ramamoorthy
    Pappo, Alberto S.
    Watt, Tanya Carens
    Norenberg, Ricarda
    Fellous, Marc Mardoche
    De la Cuesta, Esther A.
    Laetsch, Theodore Willis
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
    McDermott, R.
    van Tilburg, C. M.
    Farago, A. F.
    Kummar, S.
    Tan, D. S. W.
    Albert, C. M.
    Berlin, J.
    Lassen, U. N.
    Doz, F.
    Geoerger, B.
    Mascarenhas, L.
    Federman, N.
    Reeves, J. A.
    Dima, L.
    Brega, N.
    De La Cuesta, E.
    Laetsch, T. W.
    Hong, D. S.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1101 - S1102
  • [47] Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Hyman, D. M.
    van Tilburg, C. M.
    Albert, C. M.
    Tan, D. S. W.
    Geoerger, B.
    Farago, A. F.
    Laetsch, T. W.
    Kummar, S.
    Doz, F.
    Lassen, U. N.
    DuBois, S. G.
    McDermott, R.
    Mascarenhas, L.
    Berlin, J. D.
    Rudzinski, E. R.
    Cox, M. C.
    Nanda, S.
    Childs, B. H.
    Drilon, A.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 162 - +
  • [48] Durability of Response with Larotrectinib in Adult and Pediatric Patients with TRK Fusion Cancer
    Leyvraz, Serge
    Hyman, David M.
    van Tilburg, Cornelis M.
    Albert, Catherine M.
    Tan, Daniel Sw.
    Geoerger, Birgit
    Farago, Anna F.
    Laetsch, Theodore W.
    Kummar, Shivaani
    Doz, Francois
    Lassen, Ulrik
    Dubois, Steven G.
    Mcdermott, Ray
    Mascarenhas, Leo
    Berlin, Jordan
    Rudzinski, Erin R.
    Cox, Michael C.
    Nanda, Shivani
    Childs, Barrett H.
    Drilon, Alexander
    Hong, David S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 204 - 204
  • [49] Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Hyman, D.
    Tan, D. S. W.
    van Tilburg, C.
    Albert, C.
    Geoerger, B.
    Farago, A.
    Laetsch, T.
    Kummar, S.
    Doz, F.
    Lassen, U.
    Dubois, S.
    McDermott, R.
    Mascarenhas, L.
    Berlin, J.
    Rudzinski, E.
    Nanda, S.
    Childs, B.
    Drilon, A.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib
    Moreno Garcia, V.
    Lin, J.
    Patel, J.
    Lassen, U.
    Solomon, B.
    Rosen, L.
    Leyvraz, S.
    Tan, D. S. W.
    Reeves, J. A.
    Beckmann, G.
    Rudolph, M.
    Wierzbinska, J.
    Dima, L.
    Brega, N.
    Kummar, S.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S786 - S787
12345